This inventor holds 1 USPTO granted patent. Top assignee: Hokuriku Pharmaceutical Co., Ltd.. Active years: 1977.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1977
Title: Yuzuro Yamamoto: Innovator in Pharmaceutical Chemistry
Introduction
Yuzuro Yamamoto is a notable inventor based in Kanazawa, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as bronchodilators. His innovative work has led to the filing of a patent that showcases his expertise and dedication to improving healthcare.
Latest Patents
Yamamoto holds a patent for Hydroxyl-substituted-2-chloro-.alpha.-(Tert-butylaminomethyl)-benzylalcohol. This compound is characterized by its unique formula and is recognized for its potential use as a bronchodilator. The patent details the process for the production of these compounds, highlighting their importance in medical applications. He has 1 patent to his name, reflecting his focused contributions to the industry.
Career Highlights
Yuzuro Yamamoto is associated with Hokuriku Pharmaceutical Co., Ltd., where he has been instrumental in advancing pharmaceutical research. His work has not only contributed to the company's portfolio but has also played a role in enhancing therapeutic options available to patients. His dedication to innovation in drug development is evident in his research and patent filings.
Collaborations
Yamamoto has collaborated with esteemed colleagues such as Sakae Kurata and Hideo Kato. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further driving innovation in their field.
Conclusion
Yuzuro Yamamoto stands out as a key figure in pharmaceutical innovation, with a focus on developing compounds that can significantly impact patient care. His contributions through patents and collaborations underscore his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile